ERCC1 Predicts a Poorer Platinum-based Chemotherapy Outcome but a Better Outcome for Uracil-Tegafur in the Resected Stage I-II NSCLC
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The role of excision repair cross-complementation group 1 (ERCC1) has been controversial in non-small cell lung cancer (NSCLC) patients who received adjuvant chemotherapy with a platinum agent. We investigated ERCC1 expression in stage I-II NSCLC to clarify its significance for adjuvant chemotherapy. Methods: The ERCC1 expression profile was evaluated by immunohistochemistry and compared according to adjuvant chemotherapeutic agents in 146 patients who underwent surgical resection for stage I-II NSCLC. The patients were divided into 3 groups; adjuvant chemotherapy with a platinum based agent (18.5%, 27/146); adjuvant chemotherapy with uracil-tegafur (UFT) (40.4%, 59/146); surgery-alone (41.1%, 60/146). Results: Nuclear ERCC1 expression was detected in 71.9% (105/146) of NSCLC and was significantly associated with a shortened survival period in the group 1 patients who received the platinum based regimen after surgery. The group 2 patients who received UFT showed the longest survival period, followed by the surgery-alone group (overall survival, p=0.049; disease-free survival [DFS], p<0.001). Conclusions: These results suggest that stage I-II NSCLC patients with ERCC1 expression experience a shorter DFS period with adjuvant chemotherapy with a platinum based regimen and may benefit from adjuvant chemotherapy with UFT, instead of platinum after surgery.
Abstract
Background: The role of excision repair cross-complementation group 1 (ERCC1) has been controversial in non-small cell lung cancer (NSCLC) patients who received adjuvant chemotherapy with a platinum agent. We investigated ERCC1 expression in stage I-II NSCLC to clarify its significance for adjuvant chemotherapy. Methods: The ERCC1 expression profile was evaluated by immunohistochemistry and compared according to adjuvant chemotherapeutic agents in 146 patients who underwent surgical resection for stage I-II NSCLC. The patients were divided into 3 groups; adjuvant chemotherapy with a platinum based agent (18.5%, 27/146); adjuvant chemotherapy with uracil-tegafur (UFT) (40.4%, 59/146); surgery-alone (41.1%, 60/146). Results: Nuclear ERCC1 expression was detected in 71.9% (105/146) of NSCLC and was significantly associated with a shortened survival period in the group 1 patients who received the platinum based regimen after surgery. The group 2 patients who received UFT showed the longest survival period, followed by the surgery-alone group (overall survival, p=0.049; disease-free survival [DFS], p<0.001). Conclusions: These results suggest that stage I-II NSCLC patients with ERCC1 expression experience a shorter DFS period with adjuvant chemotherapy with a platinum based regimen and may benefit from adjuvant chemotherapy with UFT, instead of platinum after surgery.
참고문헌 (30)
- Parkin DM, "Global cancer statistics, 2002", CA Cancer J Clin, 55, pp.74~108 (2005)
- Fu JB, "Lung cancer in women: analysis of the national Surveillance, Epidemiology, and End Results database", Chest, 127, pp.768~777 (2005)
- Paz-Ares L, "Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of nonsmall- cell lung cancer", Br J Cancer, 98, pp.1608~1613 (2008)
- Novello S, "Phase II study of high-dose paclitaxel and carboplatin in previously untreated, unresectable non-small cell lung cancer", Lung Cancer, 34, pp.261~269 (2001)
- Arriagada R, "Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer", N Engl J Med, 350, pp.351~360 (2004)
- ): a randomised controlled trial, "Lancet Oncol", 2006, 719~727
- Winton T, "Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer", N Engl J Med, 352, pp.2589~2597 (2005)
- Duffy MJ, "Use of molecular markers for predicting therapy response in cancer patients", Cancer Treat Rev, 37, pp.151~159 (2011)
- Yoo SB, "Epidermal growth factor receptor mutation and p53 overexpression during the multistage progression of small adenocarcinoma of the lung", J Thorac Oncol, 5, pp.964~969 (2010)
- Lee HJ, "CD24, a novel cancer biomarker, predicting disease-free survival of non-small cell lung carcinomas: a retrospective study of prognostic factor analysis from the viewpoint of forthcoming (seventh) new TNM classification", J Thorac Oncol, 5, pp.649~657 (2010)
- Holm B, "Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine", J Clin Oncol, 27, pp.4254~4259 (2009)
- Olaussen KA, "DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy", N Engl J Med, 355, pp.983~991 (2006)
- Gazdar AF, "DNA repair and survival in lung cancer: the two faces of Janus", N Engl J Med, 356, pp.771~773 (2007)
- Li Q, "Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells", Anticancer Res, 20, pp.645~652 (2000)
- Lord RV, "Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer", Clin Cancer Res, 8, pp.2286~2291 (2002)
- Lee HW, "Expression of excision repair crosscomplementation group 1 protein predicts poor outcome in patients with small cell lung cancer", Lung Cancer, 59, pp.95~104 (2008)
- Kang CH, "The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxanebased neoadjuvant chemotherapy and surgical resection", Lung Cancer, 68, pp.478~483 (2010)
- Booton R, "ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer", J Thorac Oncol, 2, pp.902~906 (2007)
- Jeong SH, "Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy", Lung Cancer, 68(2), pp.288~294 (2010), Elsevier Ireland Ltd
- Strauss GM, "Adjuvant paclitaxel plus carboplatin compared with observation in stage IB nonsmall- cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups", J Clin Oncol, 26, pp.5043~5051 (2008)
- Pignon JP, "Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group", J Clin Oncol, 26, pp.3552~3559 (2008)
- Tanaka F, "UFT (tegafur and uracil) as postoperative adjuvant chemotherapy for solid tumors (carcinoma of the lung, stomach, colon", rectum, and breast): clinical evidence, mechanism of action, and future direction, 2007, pp.37, 923~943
- Hamada C, "Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer", J Clin Oncol, 23, pp.4999~5006 (2005)
- Kato H, "A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung", N Engl J Med, 350, pp.1713~1721 (2004)
- Chhatwani L, "Adjuvant treatment of resected lung cancer", Proc Am Thorac Soc, 6, pp.194~200 (2009)
- Wada H, "Adjuvant chemotherapy after complete resection in non-small-cell lung cancer: West Japan Study Group for Lung Cancer Surgery", J Clin Oncol, 14, pp.1048~1054 (1996)
- Nakagawa K, "Randomised study of adjuvant chemotherapy for completely resected p-stage I-IIIA non-small cell lung cancer", Br J Cancer, 95, pp.817~821 (2006)
- Tsuboi M, "The influence of tumor size, histological differentiation and smoking history in patients with completely resected stage I adenocarcinoma of the lung", J Clin Oncol, 24, pp.7197~ (2006)
- 서경진, "Platinum제로 항암 치료한 진행성 비소세포폐암종 환자에서 HER-2", neu, ERCC1과 GST-pi에 대한 연구, 2008, pp.42(6), 327~334[DOI]
- Shirota Y, "ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy", J Clin Oncol, 19, pp.4298~4304 (2001)